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Alterations in modifications of histones have been linked to deregulated expression of many genes with important roles in cancer
development and progression. The effects of these alterations have so far been interpreted from a promoter-specific viewpoint,
focussing on gene–gene differences in patterns of histone modifications. However, recent findings suggest that cancer tissues also
display cell–cell differences in total amount of specific histone modifications. This novel cellular epigenetic heterogeneity is related to
clinical outcome of cancer patients and may serve as a valuable marker of prognosis.
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Epigenetics is the study of the inheritance of phenotypes that occur
without a corresponding change in DNA sequence. The molecular
mechanisms of epigenetic inheritance as it relates to chromatin
include the three inter-related processes of DNA methylation,
genomic imprinting and histone modifications (Kouzarides, 2007).
Through small chemical moieties that covalently attach to DNA or
histones, the epigenetic processes can increase the capacity of the
genome to store and transmit biological information beyond the
DNA sequence. In cancer, in addition to sequence alterations in
the genome, there are also changes in the epigenetic information
(Jones and Baylin, 2002; Hake et al, 2004). Both DNA methylation,
including genomic imprinting, and histone modifications show
altered patterns of distribution in cancer cells. The epigenetic
alterations may occur at different stages of tumourigenesis and
thus contribute to the development and/or progression of cancer.
While different cancers share certain phenotypic hallmarks such as
unregulated growth or resistance to apoptosis (Hanahan and
Weinberg, 2000), there is a great degree of heterogeneity in both
genetic and epigenetic alterations that may give rise to these
similar phenotypes. Such genetic and epigenetic heterogeneity may
underlie the varied clinical behaviour of cancers that can range
from indolent, slow-growing to aggressive, fast-growing tumours.
A challenge in cancer therapy is to be able to predict the behaviour
of the cancer at an early stage so that appropriate treatments are
administered to patients (Ludwig and Weinstein, 2005). Clinical
outcome prediction is based generally on grade, the degree of
tumour differentiation and/or stage, a measure of tumour size and
spread beyond the primary site. However, within cancers that are
of equivalent grade and stage, there are subtypes of patients that
are molecularly heterogeneous and have different clinical out-
comes. In this regard, molecular biomarkers such as gene
expression have been useful in distinguishing subtypes of cancer
patients with distinct clinical outcomes, thereby expanding our
prognostic capabilities.
Similar to gene expression, epigenetic factors such as DNA
methylation of specific genes have also been used as biomarkers
but to a much lesser extent. In fact, despite a long and growing list
of genes with altered DNA methylation in cancer, only a few have
been related to clinical outcome of cancer patients. Even less is
known about the association between histone modifications and
outcome of cancers. While no promoter-specific histone modifica-
tions have been related to cancer prognosis, recent work indicates
that patterns of certain histone modifications, not at specific genes,
but at the level of individual cells, can be used to predict cancer
outcome (Seligson et al, 2005). In this review, I will briefly
highlight the current ‘epigenetic prognosticators’ with emphasis on
histone modifications, explore the potential underlying mechan-
isms and how they may be used to increase the effectiveness of
epigenetic drugs such as histone deacetylase inhibitors (HDACi).
DNA METHYLATION IN CANCER
Following the seminal discovery that normal and cancer cells show
differential methylation patterns, cancer epigenetics has been by
and large focussed on DNA methylation (Feinberg and Tycko,
2004). Over two decades of research has shown that, compared to
normal cells, DNA of cancer cells is generally hypomethylated,
while promoters of certain genes are hypermethylated, most
commonly in the context of CpG islands. Such promoter-specific
increase in methylation leads to silencing of the affected gene that
might have functioned as, for instance, a tumour suppressor.
Transcriptional repression by DNA methylation is mediated by a
class of methyl DNA binding proteins which, by virtue of
recognising specifically methylated DNA sequences, recruit
repressive protein complexes including histone deacetylases
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www.bjcancer.com(HDACs) to gene promoters (Klose and Bird, 2006). The
combination of CpG island methylation, proteins that binds to
them, and repressive histone modifications generates localised
regions of specialised chromatin, which can inhibit transcription.
Despite a growing list of genes including tumour suppressors
and DNA repair genes that are aberrantly hypermethylated in
different cancers, only a limited number of the identified
hypermethylated genes have demonstrated any potential utility
in clinical decision making. Nonetheless, in recent years, evidence
for clinico-pathological significance of gene-specific DNA methy-
lation has been emerging. In gliomas, methylation of the O
6-
methylguanine-DNA methyltransferase (MGMT) gene promoter is
a predictor of patients’ responsiveness to alkylating agents
(Esteller et al, 2000). O
6-methylguanine-DNA methyltransferase
is a DNA repair protein that prevents formation of toxic DNA
inter-strand crosslinks. When MGMT promoter is methylated, the
gene is not transcribed, leading to enhanced sensitivity of cells to
alkylating agents. Moreover, the predictive power of promoter
methylation may be increased when multiple promoters are
examined at once. In neuroblastoma, unbiased clustering of
several methylated CpG islands has been linked to clinical outcome
(Alaminos et al, 2004). As opposed to single-gene analysis, the
integrated information on methylation patterns of multiple genes
may reflect the functional status of several cellular pathways and
prove to be a reliable predictor of prognosis.
Loss of imprinting (LOI) – loss of parent-of-origin DNA
methylation pattern – may also contribute to carcinogenesis. For
instance, LOI of the IGF2 (insulin-like growth factor 2) gene is seen
in many patients with colorectal cancer, and biallelic expression of
IGF2 is found in the normal-appearing colonic epithelium of
colorectal cancer patients. Elevated levels of IGF2 in normal cells
may confer a growth advantage that is necessary for tumour
initiation (Sakatani et al, 2005).
HISTONE MODIFICATIONS IN CANCER BIOLOGY
In addition to DNA methylation, modifications of histones are
important determinants of epigenetic state. In eukaryotes, an
octamer of histones H2A, H2B, H3 and H4 is wrapped by 147bp of
DNA to form a nucleosome – the fundamental unit of chromatin
(Luger et al, 1997). Histones are subject to a variety of post-
translational modifications, especially on their N termini, includ-
ing acetylation (ac) of lysines (K) and methylation (me) of lysines
and arginines (R) as well as phosphorylation, ubiquitylation,
glycosylation, sumoylation, ADP-ribosylation and carbonylation.
These modifications play fundamental roles in gene regulation and
other chromatin-based processes. The enzymes that modify
histones show distinct specificities and distinguish between
histone subtypes as well as individual residues within a given
histone (Suka et al, 2001). The histone-modifying enzymes affect
histones either locally, through targeted recruitment by sequence-
specific transcription factors (Rundlett et al, 1998), or globally
throughout the genome in an untargeted manner affecting virtually
all nucleosomes (Vogelauer et al, 2000). Such widespread functions
that occur independently of apparent sequence-specific DNA-
binding proteins are referred to as ‘global’ histone modifications.
Like their targeted effects, the global activity of the histone-
modifying enzymes can modulate gene activity (Vogelauer et al,
2000). Therefore, histones are modified locally and globally
through multiple histone-modifying enzymes with different
substrate specificities, generating hierarchical patterns of mod-
ifications from single promoters to large regions of chromosomes
and even single cells. For instance, heterochromatin – highly
repetitive, transcriptionally inactive and late-replicating regions of
the genome – is generally deacetylated but could be enriched for
H3K9me2/3 (Horn and Peterson, 2006). This is in contrast to
euchromatin – gene rich and transcriptionally active regions of the
genome – which is associated with H3K4me2 and increased
acetylation (Strahl et al, 1999). Therefore, genomic distribution of
specific histone modifications may reflect the underlying organi-
zation of the genome.
Considering the fundamental roles of histone modifications, it is
not surprising that aberrations in histone modifications are
discovered in cancer. Essentially all these aberrations have been
shown to occur at individual gene promoters due to inappropriate
targeting of one or more histone-modifying enzymes. For instance,
the E2F transcription factor recruits the tumour suppressor
retinoblastoma protein (Rb) to its target genes. Rb in turn recruits
HDAC1 that leads to transcriptional silencing of genes with
important roles in tumour biology such as cyclin E (Brehm et al,
1998). Cancer-related perturbations of promoter-specific epige-
netic patterns result in improper repression or activation of genes
that could ultimately lead to cellular transformation, carcino-
genesis or cancer progression. For instance, chromatin immuno-
precipitation (ChIP; a method for determining sites of protein–
DNA interactions in vivo) experiments show that silencing of the
CDKN2A locus – which encodes the p16INK4A and p14ARF
tumour suppressors – is associated with hypermethylation of
H3K9 and hypomethylation of H3K4 (Nguyen et al, 2002).
Aberrant modification of histones associated with DNA repetitive
sequences has also been reported. These aberrations include lower
levels of histone H4K16ac and K20me3 in haematological
malignancies and colorectal adenocarcinomas (Fraga et al, 2005).
HISTONE MODIFICATIONS IN CANCER PROGNOSIS
While cancers have atypical patterns of histone modifications,
none of the locus-specific changes in histone modifications has so
far been related correlatively or causally to clinical outcome. This
is perhaps because deregulation of histone modifications at the
level of a single promoter is intimately linked to mis-expression of
the downstream gene, which in most cases may not provide
adequate information to predict clinical outcome.
In contrast to promoter-targeted histone modifications, we have
shown recently that cellular levels of histone modifications are
related to cancer prognosis (Seligson et al, 2005). Our initial
interest in the roles of histone modifications in cancer was derived
from our findings in yeast. Mapping patterns of histone
modifications at promoters to gene expression in yeast suggested
that histones can store biological information in their modification
patterns (Kurdistani et al, 2004). Extending this idea to cancer, we
wondered whether promoter-specific histone modification pat-
terns, on a genomewide scale, encode information that can be used
to predict prognosis. Determining gene-specific patterns of histone
modifications of cancer cells in primary tissue specimens can be
cumbersome due to cellular heterogeneity and tissue quantity, and
would involve high-throughput ChIP which may not be easily
adaptable by clinical laboratories. Thus, we turned our attention to
cellular patterns of histone modifications.
Since histone modifications occur throughout the genome, any
potential change in the activity or specificity of the histone-
modifying enzymes should result in detectable changes in specific
histone modifications at the level of individual nuclei by
immunostaining. This is indeed the case. Immunohistochemical
(IHC) examination of primary prostate cancer tissues with
antibodies against specific histone modifications revealed that
cancer cells display much heterogeneity in both the fraction of cells
that are positively stained and the intensity of staining (Figure 1),
parameters that are scored routinely by pathologists. Such
heterogeneous cellular staining was evident for all histone
modifications examined which included H3K4me2, K9ac, K18ac,
H4R3me2 and K12ac (Seligson et al, 2005). While the IHC
approach provides no information on the genomic, gene–gene
differences in distribution of histone modifications, it reveals novel
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hidden in molecular approaches such as ChIP.
Is the cellular heterogeneity in histone modification levels
related to prostate cancer outcome? Analysis of the levels of each
modification individually was not informative of prognosis, which
was defined as time to tumour recurrence after surgical removal of
the primary tumour. When the data from all modifications were
analysed collectively, the histone modification patterns defined
two groups of patients with significantly different risks of tumour
recurrence, independently of other clinico-pathological features. A
second prostate cancer TMA validated the prognostic power of two
of the histone modifications, H3K4me2 and K18ac (Seligson et al,
2005). So, the histone modification patterns provide additional,
non-redundant prognostic information to the known prognostic
features of prostate cancer. This finding suggests for the first time
that epigenetic heterogeneity between cancer tissues may underlie
the varied outcome of the disease. Surprisingly, the patient group
with lower cellular levels of histone modifications (i.e. decreased
percent cell staining) had poorer prognosis. This seems counter-
intuitive as the examined histone modifications are all associated
with gene activity, and so, their loss should have adverse effects on
gene expression and tumour growth. However, lower cellular levels
by IHC may represent, at a molecular level, re-distribution of a
histone modification from most histones throughout the genome
to a limited number of genes. These genes may then confer a more
aggressive phenotype to the tumour. Alternatively, reduction of
global histone modification levels may reflect conversion of
chromatin from a euchromatic to a heterochromatic state. Such
‘heterochromatinization’ of the genome may provide cells a
protective measure against genotoxic stress by limiting DNA
exposure. Although these scenarios are mere hypotheses, they can
be tested by molecular examination of histone modifications in
tumours with different cellular levels. Interestingly, a recent study
provides some evidence that cellular levels of histone modifica-
tions in prostate differ between benign, pre-neoplastic and cancer
tissues, suggesting that histone modification patterns may be
dynamic and change during various steps of carcinogenesis
(Mohamed et al, 2007).
The aberrations in cellular levels of histone modifications are
consistent with findings that histone-modifying enzymes have
impaired activity in various cancers (Esteller, 2006). For instance,
missense and truncating mutations of p300 histone acetyltransfer-
ase (HAT) and loss of heterozygosity at the p300 locus, which
could result in global reduction in histone acetylation, are
associated with multiple cancers (Gayther et al, 2000). In
leukaemia, p300 is fused to MLL through a translocation (Ida
et al, 1997), which may confine its HAT activity only to MLL-target
genes and result in diminished histone acetylation from most of
the genome. Since the balance of HAT and HDAC activities
determines the global levels of histone acetylation, impaired HDAC
activity could also contribute to cellular patterns of histone
acetylation. In fact, HDACs show deregulated expression in
multiple cancers (Ozdag et al, 2006), and HDAC6 expression
may be related to clinical outcome in breast cancer (Zhang et al,
2004; Krusche et al, 2005). A truncating mutation abolishes
HDAC2 enzymatic activity in several sporadic tumours (Ropero
et al, 2006). Histone methyltransferases (HMTs) are also
deregulated in cancer and may affect global methylation levels.
In prostate cancer, lysine-specific demethylase 1 (LSD1) over-
expression is associated with increasing grade and may be used to
predict prognosis (Kahl et al, 2006). The polycomb group protein
enhancer of zeste homologue 2 (Ezh2) is a H3K27 HMT which is
required for cell proliferation, is over-expressed in metastatic
prostate cancer and is associated with poor prognosis (Varambally
et al, 2002). The activity of histone-modifying enzymes can also be
regulated through post-translational modifications of the enzyme
complexes themselves. For instance, the kinase Akt phosphorylates
Ezh2, suppressing Ezh2 HMT activity by reducing its affinity for
histone H3, leading to global loss of histone methylation at K27
(Cha et al, 2005). Finally, histone-modifying enzymes commonly
reside in multi-protein complexes. Changes in expression of one or
more component of these complexes may not only affect the
activity of the complex but also lead to formation of complexes
with altered histone substrate specificities. For instance, over-
expression of Ezh2 in tissue culture promotes formation of a new
polycomb repressive complex 4 that acquires new substrate
specificity, methylating linker histone H1 in addition to H3K27
(Kuzmichev et al, 2005). So, while mis-targeting of histone-
modifying enzymes can generate aberrant local, promoter-specific
patterns of histone modifications, the altered activity of the
ABC
Figure 1 Cellular epigenetic heterogeneity in cancer. Immunohistochemical examination of prostate cancer tissues by an antibody against histone H3
lysine 18 acetylation reveals cell–cell differences in total levels of H3K18ac. The cells with brown nuclei are positively stained (indicated by brown block
arrows) and their increased percentage is related to better clinical outcome. The unstained nuclei are blue (indicated by blue arrows). The tissues shown are
of equivalent grade but represent (A) low, (B) medium and (C) high levels of cellular H3K18ac. Magnification: 10 , top panel; 40 , bottom panel.
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translational control, may provide a mechanism to regulate histone
modifications throughout the genome.
CELLULAR HISTONE MODIFICATION PATTERNS
AND HDAC THERAPY
The prognostic cellular histone modification patterns may not only
be used as general biomarkers but could have specific implications
for therapies involving inhibitors of HDAC (HDACi) or other
enzymes such as histone demethylases. The patients with poorer
outcome who have low levels of H3K4me2 and K18ac could
perhaps benefit more from HDACi or require a different regimen
of various epigenetic therapeutics compared to those with high
levels of both histone modifications. The current generation of
HDACi is mostly not selective and can inhibit multiple HDACs
(Minucci and Pelicci, 2006). Given the distinct in vivo specificities
of histone-modifying enzymes, IHC analysis of histone modifica-
tions may also reveal which specific modifications show the most
reduction, guiding the design and use of drugs with more
restricted targets.
Histone deacetylase inhibitors have pleiotropic effects on cancer
cells including growth arrest, apoptosis and differentiation. These
effects are linked to transcriptional reactivation of certain genes
such as p21, which causes growth arrest (Richon et al, 2000).
However, the cellular heterogeneity in histone modification
patterns suggests the possibility that HDACi may also have
broader effects. Histone deacetylase inhibitors may reduce the
heterogeneity in cellular levels of histone modifications by
increasing the prevalence of cells with higher levels of histone
acetylation. This would shift the cellular patterns to the more
favourable prognostic category (Figure 2). Since lower cellular
histone methylation levels are also associated with poorer
prognosis, demethylase inhibitors, perhaps in combination with
HDACi, could have additive or synergistic effects on modifying the
cellular patterns (Metzger et al, 2006).
CONCLUSION
Cancer is widely considered to have a clonal origin but cancer
tissues are comprised of a heterogeneous group of cells with
different functional potential. Analysis of histone modifications of
individual cells in primary cancer tissues has now revealed a new
layer of heterogeneity: cell–cell differences in total amount of
acetylation and methylation of specific histone residues. This
cellular epigenetic heterogeneity is related to the clinical outcome
of cancer patients. While promoter-specific histone modification
patterns can be established through targeted recruitment of
histone modifiers, much work remains to elucidate the molecular
determinants of variation in cellular levels of histone modifica-
tions. An ‘epigenetic model of cancer’ has been proposed to
account for epigenetic contribution to cancer development and
progression (Baylin and Ohm, 2006; Feinberg et al, 2006). In this
model, promoter-specific epigenetic alterations can result in mis-
regulation of genes which increase the risk of cancer development
and contribute to cancer progression. Whether and how the
cellular patterns of histone modifications can be incorporated into
this model remains an exciting endeavour.
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